All In MedTech

Device Trial Radar · NCT04579692

MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Phase 1 Clinical Trial for MR Guided Focused Ultrasound (FUS) Thalamotomy of Central Lateral Thalamic Nucleus for the Treatment of Medication-refractory Trigeminal Neuralgia

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

10

Actual

Start

Aug 16, 2021

Primary completion

May 28, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
University of Maryland, BaltimoreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Focused Ultrasound Foundation; InSightec
First posted
Oct 8, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating Trigeminal Neuralgia. Trigeminal Neuralgia (pain) is a type of pain involving the face that can be disabling to those it affects.

Conditions

  • Trigeminal Neuralgia

Interventions

  • ExAblate Transcranial treatmentDevice

    Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment related adverse eventsTime frame: All events will be reported up to 6 months from treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Maryland Medical Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.